Correction: Amr et al. Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort. Reviews in Cardiovascular Medicine. 2024; 25(6): 225
Ali Amr, Elham Kayvanpour, Christoph Reich, Jan Koelemen, Shamily Asokan, Norbert Frey, Benjamin Meder, Farbod Sedaghat-Hamedani · 2026
Read Correction: Amr et al. Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort. Reviews in Cardiovascular Medicine. 2024; 25(6): 225 by Ali Amr, Elham Kayvanpour, Christoph Reich, Jan Koelemen, Shamily Asokan, Norbert Frey, Benjamin Meder, Farbod Sedaghat-Hamedani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13423721.txt.
Description
Ali Amr and seven co-authors issue a correction to their 2024 study of cardiac myosin inhibitors for hypertrophic cardiomyopathy, a thickened-heart condition, in a large single-centre cohort. Errors had crept into Table 1 of the original article, and the notice supplies the corrected table in full, with an apology for the mistake.
The repaired table sets out the entry rules of two landmark trials of the drug mavacamten, EXPLORER-HCM and SEQUOIA-HCM. Criteria include an age of at least 18 and a wall thickness of 15 millimetres or more. A peak outflow gradient of at least 50 millimetres of mercury also counts, while recent fainting or dangerous rhythms exclude patients. The authors state the fix changes neither results nor conclusions.
Catalog record
| CREATOR | Ali Amr, Elham Kayvanpour, Christoph Reich, Jan Koelemen, Shamily Asokan, Norbert Frey, Benjamin Meder, Farbod Sedaghat-Hamedani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 8784 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |